US › Healthcare

Bolt Biotherapeutics (BOLT)

US · Healthcare · Biotechnology

$3.35-7.85%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$5,000

Revenue YoY

-99.7%

Net profit

$-7.7M

EPS

$-4.57

EPS estimate

$-2.97

Net margin

-154,400.0%

EPS came in at -4.57 against a street estimate of -2.97 — a miss of 53.9%.

Key statistics

Market cap

$7.6M

Forward P/E

0.0

P/B

0.57

Book value

$6.56

EPS (TTM)

$-17.48

52-week high

$7.20

52-week low

$3.13

50-day MA

$3.86

200-day MA

$4.73

Beta

1.09

Analyst view

Analysts rate Bolt Biotherapeutics a buy (1 buy, 3 hold, 0 sell out of 4) with an average price target of $29.00.

Shareholding

Insiders

3.46%

Institutions

27.92%

Largest institutional holders

Fund	Stake
Sofinnova Ventures	7.15%
Renaissance Technologies Corp	4.01%
Vivo Capital, LLC	3.76%
T3 Companies, LLC	1.97%
Board of Ttees Leland Stanford Jr Univ	1.87%
Pfizer Inc	1.63%
Lynx1 Capital Management, LP	1.60%
Geode Capital Management, LLC	1.49%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bolt Biotherapeutics — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.